Compare Amphastar Pharmaceuticals Inc (AMPH) vs Nvidia Corp (NVDA) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

NVIDIA (NVDA) trades at $210.96, up 4.07% in the last session, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.87 exceeding the $1.76 estimate. Revenue surged to $130.50 billion in 2025, driving a net income margin of 62.97%. Analyst consensus is strongly bullish, with a price target of $324.95.

The outlook remains positive due to NVIDIA's AI chip dominance and accelerating revenue growth, though risks include peak AI spending concerns and increased competition. The stock offers significant upside to the consensus target, but investors should weigh valuation multiples against execution risks in a dynamic market.